Ratnoff O D, Saito H
Proc Natl Acad Sci U S A. 1979 Feb;76(2):958-61. doi: 10.1073/pnas.76.2.958.
To investigate the earliest steps of the intrinsic clotting pathway, Hageman factor (Factor XII) was exposed to Sephadex gels to which ellagic acid had been adsorbed; Hageman factor was then separated from the gels and studied in the fluid phase. Sephadex-ellagic acid-exposed Hageman factor, whether purified or in plasma, activated plasma thromboplastin antecedent, but only when high molecular weight kininogen was presnet. In the absence of plasma prekallikrein, maximal activation of plasma thromboplastin antecedent was slightly delayed in plasma, a delay not observed with similarly treated purified Hageman factor. Thus, high molecular weight kininogen was needed for expression of Hageman factor's clot-promoting properties and plasma prekallikrein played a minor role in the interaction of ellagic acid-treated Hageman factor and plasma thromboplastin antecedent.
为了研究内源性凝血途径的最初步骤,将哈格曼因子(因子 XII)暴露于已吸附鞣花酸的葡聚糖凝胶;然后将哈格曼因子从凝胶中分离出来,并在液相中进行研究。暴露于葡聚糖 - 鞣花酸的哈格曼因子,无论纯化与否或存在于血浆中,均可激活血浆促凝血酶原激酶,但仅在高分子量激肽原存在时才会激活。在缺乏血浆前激肽释放酶的情况下,血浆中血浆促凝血酶原激酶的最大激活略有延迟,而经类似处理的纯化哈格曼因子未观察到这种延迟。因此,高分子量激肽原是哈格曼因子促凝特性表达所必需的,而血浆前激肽释放酶在鞣花酸处理的哈格曼因子与血浆促凝血酶原激酶的相互作用中起次要作用。